Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population

被引:241
作者
Kubota, T
Chiba, K
Ishizaki, T
机构
[1] INT MED CTR JAPAN,RES INST,DEPT CLIN PHARMACOL,SHINJUKU KU,TOKYO 162,JAPAN
[2] SRL INC,CTR MOL BIOL & CYTOGENET,HACHIOJI,TOKYO,JAPAN
关键词
D O I
10.1016/S0009-9236(96)90214-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To assess the genotype pattern of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Methods: One hundred eighty-six unrelated, healthy Japanese subjects were genotyped for S-mephenytoin 4'-hydroxylase (CYP2C19) according to a genotyping technique to identify the wild-type (wt) gene and two mutations, CYP2C19(m1) in exon 5 and CYP2C19(m2) in exon 4. Fourty-six of the 186 subjects genotyped were phenotyped with racemic mephenytoin using the conventional 8-hour urine analysis of 4'-hydroxymephenytoin. Results: The frequency of poor metabolizers by the genotyping analysis was 18.8% (35 of the 186 subjects), consisting of 12 homozygous for CYP2C19(m1) (m1/m1), three homozygous for CYP2C19(m2) (m2/m2), and 20 heterozygous for the two defects (m1/m2). Thus the allele frequencies of CYP2C19(m1) and CYP2C19(m2) were calculated to be 0.29 and 0.13 (107 and 46 of the total of 372 alleles), respectively. Among the 46 subjects phenotyped, seven were identified as the poor metabolizers, with a log(10) urinary excretion of 4'-hydroxymephenytoin of < 0.3% of the racemic dose. These seven subjects were genotyped as the individuals with the m1/m1 (two), m1/m2 (four) or m2/m2 (one) allele combination, indicating a complete concordance between the phenotyping and genotyying tests. Conclusion: The present genotyping test confirmed that the frequency of CYP2C19 mutant gene m1 is about 2.2 times greater than another mutant gene, m2, among Japanese poor metabolizers. The genotyping of CYP2C19 discriminates between the two S-mephenytoin 4'-hydroxylation phenotypes completely in the Japanese subjects.
引用
收藏
页码:661 / 666
页数:6
相关论文
共 28 条
[1]   HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].
ALVAN, G ;
BECHTEL, P ;
ISELIUS, L ;
GUNDERTREMY, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537
[2]   POLYMORPHIC HYDROXYLATION OF S-MEPHENYTOIN AND OMEPRAZOLE METABOLISM IN CAUCASIAN AND CHINESE SUBJECTS [J].
ANDERSSON, T ;
REGARDH, CG ;
LOU, YC ;
ZHANG, Y ;
DAHL, ML ;
BERTILSSON, L .
PHARMACOGENETICS, 1992, 2 (01) :25-31
[3]   THE HYDROXYLATION OF OMEPRAZOLE CORRELATES WITH S-MEPHENYTOIN METABOLISM - A POPULATION STUDY [J].
BALIAN, JD ;
SUKHOVA, N ;
HARRIS, JW ;
HEWETT, J ;
PICKLE, L ;
GOLDSTEIN, JA ;
WOOSLEY, RL ;
FLOCKHART, DA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (06) :662-669
[4]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[5]  
BROCKMOLLER J, 1995, PHARMACOGENETICS, V5, P80
[6]   ASSESSMENT OF LIVER METABOLIC FUNCTION - CLINICAL IMPLICATIONS [J].
BROCKMOLLER, J ;
ROOTS, I .
CLINICAL PHARMACOKINETICS, 1994, 27 (03) :216-248
[7]   A MULTIFAMILY STUDY ON THE RELATIONSHIP BETWEEN CYP2C19 GENOTYPE AND S-MEPHENYTOIN OXIDATION PHENOTYPE [J].
BROSEN, K ;
DEMORAIS, SMF ;
MEYER, UA ;
GOLDSTEIN, JA .
PHARMACOGENETICS, 1995, 5 (05) :312-317
[8]  
CHIBA K, 1993, J PHARMACOL EXP THER, V266, P52
[9]   GENETICALLY VARIABLE METABOLISM OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS IN MAN [J].
DAHL, ML ;
BERTILSSON, L .
PHARMACOGENETICS, 1993, 3 (02) :61-70
[10]  
DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594